<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01971684</url>
  </required_header>
  <id_info>
    <org_study_id>P00008709</org_study_id>
    <nct_id>NCT01971684</nct_id>
  </id_info>
  <brief_title>ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP</brief_title>
  <acronym>ICON1</acronym>
  <official_title>ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terrana ITP Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand physician treatment decisions in selecting
      specific second line treatments in pediatric ITP and to determine the effectiveness of
      different second line ITP treatments. Eligible patients are those ages 1-18 years who are
      starting on a new second line treatment for ITP, defined as any treatment other than IVIG,
      steroids, anti-D globulin, or aminocaproic acid. Enrolled patients remain on the study for
      approximately one year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this observational study is to model factors that determine physician
      treatment decisions in selecting specific second line agents in pediatric ITP and to
      determine the comparative effectiveness of second line ITP treatments by bleeding measures,
      platelet counts, and patient reported outcome measures. This prospective observational,
      longitudinal, multicenter cohort study will aim to collect routine clinical care data,
      quality of life information from patients, and decision making data from clinicians at
      enrollment and at regular clinical intervals for at least one year. The primary and secondary
      objectives are as follows:

      Primary Objectives:

        1. To model factors that determine physician treatment decisions in selecting specific
           second line agents in pediatric ITP.

        2. To assess patient reported outcomes with relation to specific second line pediatric ITP
           therapies.

        3. To determine the comparative effectiveness of second line ITP treatments in terms of
           bleeding and platelet counts.

      Secondary Objectives:

        1. To describe phenotypic variation among patients with refractory ITP;

        2. To assess side effects and complications related to specific treatments for refractory
           ITP;

        3. To describe monitoring and follow up practices among pediatric hematologists with each
           second line agent;

        4. To weight factors that physicians use when deciding to treat pediatric ITP patients with
           second line agents;

        5. To determine whether physician perception of patient quality of life correlates with
           patient derived quality of life measures;

        6. To measure the correlation between the ITP Bleeding Scale and the Bleeding Assessment
           Tool in refractory pediatric ITP patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in patient reported outcomes</measure>
    <time_frame>Enrollment, 1 and 12 months</time_frame>
    <description>Kids ITP Tool, Memorial Symptom Assessment Scale, Fatigue Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in bleeding assessment</measure>
    <time_frame>Enrollment, 1, 6, and 12 months</time_frame>
    <description>ITP Bleeding Scale, Bleeding Assessment Tool</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in platelet count</measure>
    <time_frame>over 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects and complications of treatments</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Refractory Pediatric ITP Patients</arm_group_label>
    <description>Pediatric ITP patients, ages 1-18, starting a new second line ITP therapy, defined as not IVIG, steroids, anti-D, or aminocaproic acid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Second Line ITP agents</intervention_name>
    <description>The treating physicians will select the second line agent and clinical data will be collected.</description>
    <arm_group_label>Refractory Pediatric ITP Patients</arm_group_label>
    <other_name>rituximab</other_name>
    <other_name>6-mercaptopurine</other_name>
    <other_name>mycophenolate mofetil</other_name>
    <other_name>sirolimus</other_name>
    <other_name>splenectomy</other_name>
    <other_name>romiplostim</other_name>
    <other_name>eltrombopag</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric refractory ITP patients starting on a new second line therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Immune Thrombocytopenia or Evans Syndrome

          -  Ages &gt; 12 months to &lt;18 years

          -  Starting a new second line therapy as defined as any therapy except IVIG, steroids,
             anti-D globulin, or aminocaproic acid

          -  Starting a single agent/monotherapy

        Exclusion Criteria:

          -  Evans Syndrome with a history of or current evidence of autoimmune hemolytic anemia

          -  Unwillingness to be followed for 1 year

          -  Physician providing care is unwilling to participate

          -  Patient is starting multiple second line agents simultaneously
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mattel Children's Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF School of Medicine</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Children's Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Whitcomb Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Hospital &amp; Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goryeb Children's Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian University Hospital of Columbia and Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hasbro Children's Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>KIH8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U. de Montreal CHU St. Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2013</study_first_submitted>
  <study_first_submitted_qc>October 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2013</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Rachael Grace</investigator_full_name>
    <investigator_title>Principal Investigator, PKD Natural History Study</investigator_title>
  </responsible_party>
  <keyword>ITP</keyword>
  <keyword>idiopathic thrombocytopenic purpura</keyword>
  <keyword>bleeding score</keyword>
  <keyword>platelet count</keyword>
  <keyword>health-related quality of life</keyword>
  <keyword>HRQL</keyword>
  <keyword>Purpura</keyword>
  <keyword>Purpura, Thrombocytopenic</keyword>
  <keyword>Purpura, Thrombocytopenic, Idiopathic</keyword>
  <keyword>Blood Coagulation Disorders</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>Skin Manifestations</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Blood Platelet Disorders</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Hemorrhagic Disorders</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Therapeutic Uses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

